CO2022004545A2 - Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapéuticas - Google Patents
Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapéuticasInfo
- Publication number
- CO2022004545A2 CO2022004545A2 CONC2022/0004545A CO2022004545A CO2022004545A2 CO 2022004545 A2 CO2022004545 A2 CO 2022004545A2 CO 2022004545 A CO2022004545 A CO 2022004545A CO 2022004545 A2 CO2022004545 A2 CO 2022004545A2
- Authority
- CO
- Colombia
- Prior art keywords
- humanized anti
- antibodies
- therapeutic applications
- chemokine receptor
- receptor type
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102100031011 Chemerin-like receptor 1 Human genes 0.000 abstract 1
- 101000919756 Homo sapiens Chemerin-like receptor 1 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- AOPOCGPBAIARAV-OTBJXLELSA-N resolvin E1 Chemical compound CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O AOPOCGPBAIARAV-OTBJXLELSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona compuestos humanizados anti-CMKLR1 que tienen una capacidad agonista en la interacción entre Resolvina E1 y CMKLR1, y sus usos para tratar o prevenir una enfermedad, en particular en la que la resolución de la inflamación se retrasa o se interrumpe. (Sin figura)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19306323.7A EP3804754A1 (en) | 2019-10-09 | 2019-10-09 | Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications |
EP19306322 | 2019-10-09 | ||
PCT/EP2020/078488 WO2021069709A1 (en) | 2019-10-09 | 2020-10-09 | Anti-chemokin like receptor 1 humanized antibodies and their therapeutic applications |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022004545A2 true CO2022004545A2 (es) | 2022-07-08 |
Family
ID=72811872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0004545A CO2022004545A2 (es) | 2019-10-09 | 2022-04-08 | Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapéuticas |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240084019A1 (es) |
EP (1) | EP4041302A1 (es) |
JP (1) | JP2022552490A (es) |
KR (1) | KR20220087466A (es) |
CN (1) | CN114786722A (es) |
AU (1) | AU2020365034A1 (es) |
CA (1) | CA3156835A1 (es) |
CO (1) | CO2022004545A2 (es) |
CR (1) | CR20220155A (es) |
IL (1) | IL292029A (es) |
MX (1) | MX2022004312A (es) |
PE (1) | PE20221413A1 (es) |
WO (1) | WO2021069709A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024028508A2 (en) | 2022-08-05 | 2024-02-08 | Ose Immunotherapeutics | Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis |
WO2024028509A2 (en) | 2022-08-05 | 2024-02-08 | Ose Immunotherapeutics | Treatment of an inflammation-associated disease in a patient expressing high chemerin level |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7419658B2 (en) * | 2001-07-09 | 2008-09-02 | Euroscreen S.A. | Isolated ligand of ChemerinR |
US20030096299A1 (en) * | 2001-07-09 | 2003-05-22 | Valerie Wittamer | Natural ligand of G protein coupled receptor ChemR23 and uses thereof |
US20050202029A1 (en) * | 2003-10-03 | 2005-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Family of cystatin-related chemoattractant proteins |
US20070286863A1 (en) * | 2006-05-17 | 2007-12-13 | Christopher Sinal | CMKLR regulation of adipogenesis and adipocyte metabolic function |
US8038992B2 (en) * | 2008-05-10 | 2011-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Target for regulating multiple sclerosis |
WO2012172336A2 (en) * | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
AU2019247068A1 (en) * | 2018-04-03 | 2020-10-22 | Ose Immunotherapeutics | Anti-chemokin like receptor 1 antibodies and their therapeutic applications |
-
2020
- 2020-10-09 PE PE2022000588A patent/PE20221413A1/es unknown
- 2020-10-09 US US17/767,606 patent/US20240084019A1/en active Pending
- 2020-10-09 CN CN202080084501.6A patent/CN114786722A/zh active Pending
- 2020-10-09 IL IL292029A patent/IL292029A/en unknown
- 2020-10-09 CA CA3156835A patent/CA3156835A1/en active Pending
- 2020-10-09 KR KR1020227015533A patent/KR20220087466A/ko unknown
- 2020-10-09 EP EP20789120.1A patent/EP4041302A1/en active Pending
- 2020-10-09 JP JP2022521452A patent/JP2022552490A/ja active Pending
- 2020-10-09 CR CR20220155A patent/CR20220155A/es unknown
- 2020-10-09 WO PCT/EP2020/078488 patent/WO2021069709A1/en active Application Filing
- 2020-10-09 MX MX2022004312A patent/MX2022004312A/es unknown
- 2020-10-09 AU AU2020365034A patent/AU2020365034A1/en active Pending
-
2022
- 2022-04-08 CO CONC2022/0004545A patent/CO2022004545A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220087466A (ko) | 2022-06-24 |
IL292029A (en) | 2022-06-01 |
WO2021069709A1 (en) | 2021-04-15 |
JP2022552490A (ja) | 2022-12-16 |
MX2022004312A (es) | 2022-08-16 |
AU2020365034A1 (en) | 2022-04-21 |
US20240084019A1 (en) | 2024-03-14 |
CN114786722A (zh) | 2022-07-22 |
CA3156835A1 (en) | 2021-04-15 |
EP4041302A1 (en) | 2022-08-17 |
CR20220155A (es) | 2022-12-15 |
PE20221413A1 (es) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022004545A2 (es) | Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapéuticas | |
CL2018003563A1 (es) | Anticuerpos anti-c5 y usos de los mismos. | |
DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
MX2020004129A (es) | Anticuerpos anti-cd38 y metodos de uso. | |
CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
BR112018011058A2 (pt) | ?anticorpo, composição, método para tratamento de um indivíduo tendo um câncer, kit de partes, e, uso de um anticorpo ou composição? | |
CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
PE20211915A1 (es) | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso | |
CL2020003256A1 (es) | Métodos para el tratamiento del cáncer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecíficos. | |
MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
MX2021005394A (es) | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). | |
CL2023001377A1 (es) | Anticuerpos anti-npr1 y usos de los mismos | |
MX2020012081A (es) | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. | |
CO2021007691A2 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
EA201890578A1 (ru) | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли | |
AR107893A1 (es) | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE | |
MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
BR112022001336A2 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
CL2021003335A1 (es) | Anticuerpo biespecífico para a-syn/igf1r y uso de este. | |
BR112022001329A2 (pt) | Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo |